港口生物Med和中国Evinova合作伙伴利用人工智能和数字工具加快免疫学和肿瘤学的生物药物开发。 Harbour BioMed and Evinova China partner to use AI and digital tools to speed biologic drug development in immunology and oncology.

港湾生物医学和中国Evinova建立了战略伙伴关系,利用人工智能和数字工具加速生物药物的开发,重点是免疫学和肿瘤学。 Harbour BioMed and Evinova China have formed a strategic partnership to use artificial intelligence and digital tools to speed up the development of biologic drugs, focusing on immunology and oncology. 这项合作将Harbour BioMed的抗体技术,包括 Harbour Mice®平台和HBICE®/HBICATM系统,与Evinova China的AI驱动的临床开发解决方案和数字战略专业知识结合起来. The collaboration combines Harbour BioMed’s antibody technologies, including its Harbour Mice® platform and HBICE®/HBICATM systems, with Evinova China’s AI-driven clinical development solutions and digital strategy expertise. 目标是创造一个开放的生态系统,提高研究效率,加快为全球患者提供新疗法。 The goal is to create an open ecosystem that improves research efficiency and accelerates bringing new therapies to patients globally.